CJC-1295 / GHRP-6 Blend
A research peptide blend combining CJC-1295 (no DAC), a GHRH analogue, with GHRP-6, a synthetic ghrelin analogue, to synergistically elevate growth hormone levels through complementary pituitary receptor activation. Preclinical research highlights benefits in wound healing, neuroprotection, and bone health.
CJC-1295 (Mod GRF 1-29) and GHRP-6 are complementary growth hormone secretagogues that target distinct receptor systems on the hypothalamic-pituitary axis. CJC-1295 binds the GHRH receptor and stimulates GH synthesis through cAMP/PKA signaling, while GHRP-6 acts as a synthetic ghrelin analogue at the GHS-R1a receptor, additionally suppressing hypothalamic somatostatin release.
Mechanism of Action
The synergistic mechanism of CJC-1295 and GHRP-6 operates through two converging but independent signaling cascades at the anterior pituitary. CJC-1295 activates GHRH receptors coupled to Gs proteins, driving adenylyl cyclase, cAMP accumulation, and PKA-dependent GH gene transcription and granule exocytosis. GHRP-6 engages the GHS-R1a receptor coupled to Gq/11, triggering phospholipase C, inositol trisphosphate production, and intracellular calcium mobilization.
Research demonstrates that GHRP-6 raises the basal set-point of GH secretion, effectively elevating the trough level. CJC-1295 then drives pulsatile GH release from this elevated baseline, preserving the physiologic secretory pattern even under sustained stimulation (Ionescu & Frohman, 2006). GHRP-6 also acts at the hypothalamic level to suppress somatostatin, further disinhibiting GH release. As an additional benefit, GHRP-6 stimulates appetite through ghrelin-pathway activation and improves sleep architecture, both of which support the anabolic actions of elevated GH.
Reconstitution Calculator
Research
Growth Hormone Stimulation and Pulsatility
CJC-1295 preserves pulsatile GH secretion during continuous stimulation, a critical distinction from exogenous GH administration (Ionescu & Frohman, 2006). Prolonged GH and IGF-1 elevations have been demonstrated following single-dose CJC-1295 administration in healthy adults, with effects lasting several days (Teichman et al., 2006).
Bone and Growth
Elevated GH and IGF-1 from dual-pathway stimulation support osteoblast activity and bone mineral density in preclinical models. The sustained GH pulsatility preserved by CJC-1295 is particularly relevant for bone anabolism, as physiologic GH pulse patterns are more osteogenic than continuous GH exposure.
Neuroprotection
GHRP-6 and related ghrelin-pathway agonists have demonstrated neuroprotective effects. The ghrelin/GHS-R system protects hippocampal neurogenesis in chronic unpredictable mild stress models, suggesting anxiolytic and neurotrophic properties (Huang et al., 2019). Preclinical stroke studies have assessed the therapeutic time window for GHRP-6 co-administered with rhEGF, demonstrating neuroprotective and neuroregenerative effects in ischemic brain injury models (Subiros et al., 2016).
Wound Healing
GHRP-6 has shown significant wound-healing activity in preclinical models. In cutaneous wound studies, GHRP-6 enhanced the healing process and improved esthetic outcomes, with accelerated re-epithelialization and reduced scarring (Mendoza Mari et al., 2016). Further proteomic analysis revealed that GHRP-6 prevents cutaneous hypertrophic scarring through early modulation of extracellular matrix proteins and inflammatory mediators (Fernandez-Mayola et al., 2018).
Safety Profile
In preclinical and early clinical studies, both components demonstrate generally acceptable safety profiles. CJC-1295 (no DAC) is associated with transient injection-site reactions, flushing, and occasional headache. GHRP-6 may cause dose-dependent increases in appetite (a direct ghrelin-pathway effect), transient cortisol and prolactin elevation, and water retention at higher doses. GHRP-6 has a stronger appetite-stimulating effect than other GHRPs, which may be undesirable in some research contexts. No unique adverse effects have been attributed to the combination beyond those of the individual peptides. Long-term human safety data remain limited.
Pharmacokinetic Profile
CJC-1295 / GHRP-6 Blend — Pharmacokinetic Curve
Subcutaneous injectionQuick Start
- Route
- Subcutaneous injection
Research Protocols
subcutaneous Injection
Administered via subcutaneous injection.
What to Expect
What to Expect
Rapid onset expected; half-life of CJC-1295 (no DAC): ~30 minutes; GHRP-6: ~2-3 hours indicates fast-acting pharmacokinetics
Due to short half-life (CJC-1295 (no DAC): ~30 minutes; GHRP-6: ~2-3 hours), effects are expected per-dose; consistent daily administration maintains...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Multiple peer-reviewed studies available
Caution
- Injection site reactions reported
Frequently Asked Questions
References (6)
- [4]Fernandez-Mayola M et al Growth hormone-releasing peptide 6 prevents cutaneous hypertrophic scarring: early mechanistic data from a proteome study Int Wound J (2018)
- [1]Ionescu M, Frohman LA Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295 J Clin Endocrinol Metab (2006)
- [2]Teichman SL et al Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults J Clin Endocrinol Metab (2006)
- [5]Huang HJ et al The protective effects of Ghrelin/GHSR on hippocampal neurogenesis in CUMS mice Neuropharmacology (2019)
- [6]Subiros N et al Assessment of dose-effect and therapeutic time window in preclinical studies of rhEGF and GHRP-6 coadministration for stroke therapy Neurol Res (2016)
- [3]Mendoza Mari Y et al Growth Hormone-Releasing Peptide 6 Enhances the Healing Process and Improves the Esthetic Outcome of the Wounds Plast Surg Int (2016)
CJC-1295 / GHRP-2 Blend
CJC-1295 (Mod GRF 1-29) and GHRP-2 are two growth hormone secretagogues that target complementary receptor systems on anterior pituitary somatotrophs. CJC-1295
CJC-1295 / Hexarelin Blend
CJC-1295 (Mod GRF 1-29) and Hexarelin are complementary growth hormone secretagogues that target the GHRH receptor and the GHS-R1a/CD36 receptor systems, respec